ESR1 and breast neoplasm: Altogether, these data demonstrate that breast tumors with low-positive (1–9%) and intermediate-positive (10–50%) ER expression are comparable to ER-negative tumors in terms of sTILs, CD8 + T cells and PD-L1 expression.